These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23631176)

  • 1. [Clinical characteristics and management of proarrhythmias during antiarrhythmic therapy].
    Kobayashi Y
    Nihon Rinsho; 2013 Jan; 71(1):79-85. PubMed ID: 23631176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety considerations in the pharmacological management of atrial fibrillation.
    Camm AJ
    Int J Cardiol; 2008 Jul; 127(3):299-306. PubMed ID: 18191470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dangerous arrhythmias].
    Gertsch M; Fuhrer J
    Schweiz Med Wochenschr; 1993 May; 123(17):833-43. PubMed ID: 8497770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pro-arrhythmic effects of anti-arrhythmia agents].
    Haverkamp W; Wichter T; Chen X; Hördt M; Willems S; Rotman B; Hindricks G; Kottkamp H; Borggrefe M; Breithardt G
    Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
    Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological restoration and maintenance of sinus rhythm by antiarrhythmic agents].
    Sugi K
    J Cardiol; 1999 Mar; 33 Suppl 1():59-64. PubMed ID: 10342138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J
    Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sotalol and torsades de pointes ventricular tachycardia].
    Petersen HH; Sandøe E
    Ugeskr Laeger; 1996 May; 158(19):2711-6. PubMed ID: 8744073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of amiodarone in recent-onset atrial fibrillation after ibutilide has failed to restore sinus rhythm.
    Sideris S; Bonios M; Melexopoulou C; Exarchos P; Tsatiris K; Kogias J
    Cardiology; 2007; 107(4):399-401. PubMed ID: 17284902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
    Steinbeck G
    Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of atrial fibrillation, what to know on old and new antiarrhythmics].
    Le Heuzey JY
    Ann Cardiol Angeiol (Paris); 2010 Dec; 59 Suppl 1():S24-7. PubMed ID: 21211622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation.
    Agusala K; Oesterle A; Kulkarni C; Caprio T; Subacius H; Passman R
    Pacing Clin Electrophysiol; 2015 Apr; 38(4):490-8. PubMed ID: 25626340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacologic treatment of atrial fibrillation].
    Lelakowski J
    Pol Merkur Lekarski; 2008 Oct; 25(148):303-8. PubMed ID: 19145926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
    Pratt CM; Al-Khalidi HR; Brum JM; Holroyde MJ; Schwartz PJ; Marcello SR; Borggrefe M; Dorian P; Camm AJ;
    J Am Coll Cardiol; 2006 Aug; 48(3):471-7. PubMed ID: 16875971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiarrhythmic treatments of permanent atrial fibrillation].
    Lamaison D; Laureille B
    Rev Prat; 1993 Jun; 43(12):1523-31. PubMed ID: 8235408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flecainide-associated bradycardia-dependent torsade de pointes: another potential mechanism of proarrhythmia.
    Kim HS; Pak HN; Park JS; Kim SS
    Pacing Clin Electrophysiol; 2013 Mar; 36(3):e84-6. PubMed ID: 21029131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ventricular pro-arrhythmic effects of anti-arrhythmia drugs].
    Jaillon P; Simon T
    Therapie; 1992; 47(3):187-92. PubMed ID: 1295119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.